The Effect of Increasing Dialysate Magnesium on Serum Calcification Propensity in Subjects with End Stage Kidney Disease: A Randomized, Controlled Clinical Trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Serum calcification propensity is a novel functional test that quantifies the functionality of the humeral system of calcification control.

Serum calcification propensity is measured by T50, the time taken to convert from primary to secondary calciprotein particle in the serum.

Why It Was Studied

This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2018_08_21_CJASNPodcast_18_9_B.mp3.

Who Took Part

PubMed indexes the participants as middle-aged adults, older adults and people over 80, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and parallel-group study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

The Vitamin D, K2, Magnesium and Zinc group and the comparison group ran side by side rather than switching.

The primary end point was the value of T50 at the end of the intervention.

What Was Measured

The subject headings attached to it are Calcinosis, Calcium Phosphates, Dialysis Solutions, Hematologic Tests, Kidney Failure, Chronic, Magnesium and Propensity Score.

The authors tagged it with the keywords Bicarbonates, Calcification, Physiologic, Confidence Intervals, Humerus, alpha-2-HS-Glycoprotein and cardiovascular disease.

What This Means in Plain Language

The paper is a randomized, double-blind and parallel-group study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (Clinical journal of the American Society of Nephrology : CJASN), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.